DESOLO – SiT peri-launch: A comparison of Symbicort Single inhaler Therapy and conventional best practice for the treatment of persistent asthma in adults
Study identifier:D5890L00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults - a 26-week, randomised, open-label, parallel-group, multicentre study
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Symbicort, used twice daily (b.i.d) and as needed (prn), Budesonide Turbuhaler 200 µg, Fluticasone Discus 250 µg, Formoterol Turbuhaler 4.5 µg, Terbutaline Turbuhaler 0.5 mg, Salbutamol pressurized metered dose inhaler (pMDI) 100 µg, Salmeterol Discus 50 µg, Budesonide/Formoterol Turbuhaler 160/4.5 µg, Fluticasone/Salmeterol Discus 250/50 µg, Fluticasone/Salmeterol Discus 500/50 µg, Theophylline 200 mg, Theophylline 300 mg, Singulair 10 mg
Sex
All
Actual Enrollment
1600
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 2004
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Heinrich Worth
Klinikum Fürth
